Baseline patient demographics across ELN 2022 risk groups
| Characteristic . | Overall N = 513, n/N (%) . | Favorable n = 147, n/N (%) . | Intermediate n = 121, n/N (%) . | Adverse n = 245, n/N (%) . | P value . | q-value . |
|---|---|---|---|---|---|---|
| Age (y) at diagnosis∗ | 62 (18-88) | 56 (18-83) | 59 (18-87) | 66 (21-88) | < .001 | < .001 |
| Biological sex | < .001 | < .001 | ||||
| Female | 225 of 513 (44) | 69 of 147 (47) | 71 of 121 (59) | 85 of 245 (35) | ||
| Male | 288 of 513 (56) | 78 of 147 (53) | 50 of 121 (41) | 160 of 245 (65) | ||
| Reported race | .56 | .71 | ||||
| White | 322 of 369 (87) | 96 of 113 (85) | 77 of 86 (90) | 149 of 170 (88) | ||
| Black | 13 of 369 (3.5) | 5 of 113 (4.4) | 2 of 86 (2.3) | 6 of 170 (3.5) | ||
| Multiracial | 3 of 369 (0.8) | 2 of 113 (1.8) | 1 of 86 (1.2) | 0 of 170 (0) | ||
| Pacific Islander | 3 of 369 (0.8) | 2 of 113 (1.8) | 1 of 86 (1.2) | 0 of 170 (0) | ||
| Asian | 9 of 369 (2.4) | 4 of 113 (3.5) | 1 of 86 (1.2) | 4 of 170 (2.4) | ||
| Declined | 3 of 369 (0.8) | 1 of 113 (0.9) | 1 of 86 (1.2) | 1 of 170 (0.6) | ||
| Unknown | 16 of 369 (4.3) | 3 of 113 (2.7) | 3 of 86 (3.5) | 10 of 170 (5.9) | ||
| Secondary AML | 82 of 513 (16) | 3 of 147 (2.0) | 6 of 121 (5.0) | 73 of 245 (30) | < .001 | < .001 |
| Prior MDS | 44 of 513 (8.6) | 3 of 147 (2.0) | 1 of 121 (0.8) | 40 of 245 (16.3) | ||
| Prior MDS/MPN | 14 of 513 (2.7) | 0 of 147 (0) | 2 of 121 (1.7) | 12 of 245 (4.9) | ||
| Prior MPN | 24 of 513 (4.7) | 0 of 147 (0) | 3 of 121 (2.5) | 21 of 245 (8.6) | ||
| Extramedullary AML† | 20 of 513 (3.9) | 7 of 147 (4.8) | 4 of 121 (3.3) | 9 of 245 (3.7) | .83 | .9 |
| Received treatment | 456 of 513 (89) | 136 of 147 (93) | 106 of 121 (88) | 214 of 245 (87) | < .001 | < .001 |
| Intensive | 345 of 456 (76) | 117 of 136 (86) | 92 of 106 (87) | 136 of 214 (64) | ||
| HMA-based/lower-intensity | 90 of 456 (20) | 16 of 136 (12) | 10 of 106 (9.4) | 64 of 214 (30) | ||
| Targeted therapy | 21 of 456 (4.6) | 3 of 136 (2.2%) | 4 of 106 (3.8) | 14 of 214 (6.5) | ||
| Received HCT | 165 of 456 (36) | 39 of 136 (29) | 56 of 106 (53) | 70 of 214 (33) | < .001 | .001 |
| Bone marrow blasts, % | 69 (0-98) | 71 (4-97) | 79 (0-97) | 60 (2-98) | < .001 | < .001 |
| Peripheral blood blasts, % | 50 (0-99) | 55 (0-99) | 70 (0-99) | 39 (0-98) | < .001 | < .001 |
| Hemoglobin, g/dL | 8.40 (3.70-16.10) | 8.40 (4.60-15.00) | 8.70 (3.70-15.50) | 8.30 (4.60-16.10) | .81 | .9 |
| Platelets, 103/ | 45 (4-916) | 42 (8-358) | 44 (8-330) | 48 (4-916) | .92 | .92 |
| Characteristic . | Overall N = 513, n/N (%) . | Favorable n = 147, n/N (%) . | Intermediate n = 121, n/N (%) . | Adverse n = 245, n/N (%) . | P value . | q-value . |
|---|---|---|---|---|---|---|
| Age (y) at diagnosis∗ | 62 (18-88) | 56 (18-83) | 59 (18-87) | 66 (21-88) | < .001 | < .001 |
| Biological sex | < .001 | < .001 | ||||
| Female | 225 of 513 (44) | 69 of 147 (47) | 71 of 121 (59) | 85 of 245 (35) | ||
| Male | 288 of 513 (56) | 78 of 147 (53) | 50 of 121 (41) | 160 of 245 (65) | ||
| Reported race | .56 | .71 | ||||
| White | 322 of 369 (87) | 96 of 113 (85) | 77 of 86 (90) | 149 of 170 (88) | ||
| Black | 13 of 369 (3.5) | 5 of 113 (4.4) | 2 of 86 (2.3) | 6 of 170 (3.5) | ||
| Multiracial | 3 of 369 (0.8) | 2 of 113 (1.8) | 1 of 86 (1.2) | 0 of 170 (0) | ||
| Pacific Islander | 3 of 369 (0.8) | 2 of 113 (1.8) | 1 of 86 (1.2) | 0 of 170 (0) | ||
| Asian | 9 of 369 (2.4) | 4 of 113 (3.5) | 1 of 86 (1.2) | 4 of 170 (2.4) | ||
| Declined | 3 of 369 (0.8) | 1 of 113 (0.9) | 1 of 86 (1.2) | 1 of 170 (0.6) | ||
| Unknown | 16 of 369 (4.3) | 3 of 113 (2.7) | 3 of 86 (3.5) | 10 of 170 (5.9) | ||
| Secondary AML | 82 of 513 (16) | 3 of 147 (2.0) | 6 of 121 (5.0) | 73 of 245 (30) | < .001 | < .001 |
| Prior MDS | 44 of 513 (8.6) | 3 of 147 (2.0) | 1 of 121 (0.8) | 40 of 245 (16.3) | ||
| Prior MDS/MPN | 14 of 513 (2.7) | 0 of 147 (0) | 2 of 121 (1.7) | 12 of 245 (4.9) | ||
| Prior MPN | 24 of 513 (4.7) | 0 of 147 (0) | 3 of 121 (2.5) | 21 of 245 (8.6) | ||
| Extramedullary AML† | 20 of 513 (3.9) | 7 of 147 (4.8) | 4 of 121 (3.3) | 9 of 245 (3.7) | .83 | .9 |
| Received treatment | 456 of 513 (89) | 136 of 147 (93) | 106 of 121 (88) | 214 of 245 (87) | < .001 | < .001 |
| Intensive | 345 of 456 (76) | 117 of 136 (86) | 92 of 106 (87) | 136 of 214 (64) | ||
| HMA-based/lower-intensity | 90 of 456 (20) | 16 of 136 (12) | 10 of 106 (9.4) | 64 of 214 (30) | ||
| Targeted therapy | 21 of 456 (4.6) | 3 of 136 (2.2%) | 4 of 106 (3.8) | 14 of 214 (6.5) | ||
| Received HCT | 165 of 456 (36) | 39 of 136 (29) | 56 of 106 (53) | 70 of 214 (33) | < .001 | .001 |
| Bone marrow blasts, % | 69 (0-98) | 71 (4-97) | 79 (0-97) | 60 (2-98) | < .001 | < .001 |
| Peripheral blood blasts, % | 50 (0-99) | 55 (0-99) | 70 (0-99) | 39 (0-98) | < .001 | < .001 |
| Hemoglobin, g/dL | 8.40 (3.70-16.10) | 8.40 (4.60-15.00) | 8.70 (3.70-15.50) | 8.30 (4.60-16.10) | .81 | .9 |
| Platelets, 103/ | 45 (4-916) | 42 (8-358) | 44 (8-330) | 48 (4-916) | .92 | .92 |